Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27829921 | 0.98 | NISCH (0.35) | NISCHFKBP5CRBN | |
| SCHEMBL37822 | 0.90 | — | — | |
| SCHEMBL6319373 | 0.88 | — | — | |
| SCHEMBL11257556 | 0.85 | — | — | |
| SCHEMBL6322559 | 0.80 | — | — | |
| SCHEMBL4768192 | 0.76 | HRH4 (0.37) | — | |
| SCHEMBL2326328 | 0.72 | — | — | |
| SCHEMBL205175 | 0.69 | — | — | |
| SCHEMBL20629284 | 0.66 | CHRM3 (0.36) | NISCHFKBP5CRBNCCR2 | |
| SCHEMBL20629771 | 0.66 | CHRM3 (0.36) | NISCHFKBP5CRBNCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| WO-2021154976-A1 | METHODS OF TREATING BRAIN CANCER WITH PANOBINOSTAT | SECURA BIO, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| EP-2139850-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2018-09-12 | — | — | EP | disclosed |
| US-9636298-B2 | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs | METHYLGENE INC (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2005-02-10 | — | — | US | disclosed |
| US-6833384-B2 | E. g., N-Hydroxy-3-(4-(((2-(1H-indol-3-yl)-ethyl)amino)-amino)methyl)-phenyl)-2E-2 -propenamide; histone deacetylase inhibitors; antiproliferative agents; antitumor agents; anticarcinogenic agents | NOVARTIS AG (CH) | 2004-12-21 | — | — | US | disclosed |
| WO-2004103358-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | NOVARTIS AG (CH) | 2004-12-02 | — | — | WO | disclosed |
| EP-1443967-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | Novartis AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20040024067-A1 | Deacetylase inhibitors | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2004-02-05 | — | — | US | disclosed |
| EP-1318980-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2003-06-18 | — | — | EP | disclosed |
| WO-2003039599-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| US-6552065-B2 | Antiproliferative agents | NOVARTIS AG (CH) | 2003-04-22 | — | — | US | disclosed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | NISCH 3193/4885FKBP5 672/4885CRBN 2603/4885 |
| US-20040024067-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | NISCH 4178/4885FKBP5 1285/4885CRBN 1268/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | NISCH 4484/4885FKBP5 2030/4885CRBN 1405/4885 |
| US-20050032899-A1 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | HDAC2, HDAC9, HDAC1 | NISCH 4099/4885FKBP5 409/4885CRBN 2570/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | NISCH 2338/4885FKBP5 924/4885CRBN 331/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | NISCH 3193/4885FKBP5 672/4885CRBN 2603/4885 |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | NISCH 3432/4885FKBP5 738/4885CRBN 2416/4885 |
| US-20030018062-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | NISCH 4178/4885FKBP5 1285/4885CRBN 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.